- Research article
- Open Access
Comparisons between two biochemical markers in evaluating periodontal disease severity: a cross-sectional study
BMC Oral Health volume 14, Article number: 107 (2014)
The purpose of this study was to compare two biochemical markers, which have been previously used to determine the degrees of alveolar bone destruction, in evaluating periodontal disease severity.
The WF6 epitope of chondroitin sulfate (CS) and the alkaline phosphatase (ALP) levels were determined in gingival crevicular fluid (GCF) samples collected from patients with various degrees of disease severity, including ten patients with gingivitis (50 gingivitis sites) and 33 patients with chronic periodontitis (including gingivitis, slight, moderate, and severe periodontitis sites; n = 50 each), as well as from ten healthy volunteers (50 healthy sites) by Periopaper strips. The levels of CS and ALP were measured by an ELISA and a fluorometric assay, respectively.
The results demonstrated low levels of CS and ALP in non-destructive and slightly destructive periodontitis sites, whereas significantly high levels of these two biomolecules were shown in moderately and severely destructive sites (p < 0.05). Although a significant difference in CS levels was found between moderate and severe periodontitis sites, no difference in ALP levels was found. Stronger correlations were found between CS levels and periodontal parameters, including probing depth, loss of clinical attachment levels, gingival index and plaque index, than between ALP levels and these parameters.
It is suggested that the CS level is a better diagnostic marker than the ALP level for evaluating distinct severity of chronic periodontitis.
At present, diagnosis of periodontal diseases and evaluation of their severity are based on conventional clinical parameters and radiographic findings. However, these methods cannot rapidly detect early periodontal tissue losses and are, therefore, insufficient to determine the degrees of disease severity. Therefore, different types of adjunctive tools are introduced into clinical practice and provide more validity for correct diagnosis and proper treatment planning . Up to the present, several biomarkers have been used for diagnosis and assessment of periodontal disease status as well as prognostic prediction of periodontal disease progression because of their sensitivity and specificity. A number of previous studies have recommended gingival crevicular fluid (GCF), a serum exudate, as a source of biomolecules sampling in order to evaluate periodontal disease status [2–4]. GCF constituents are composed of more than 65 components that have been reported as possible biomarkers for periodontal disease progression . These include inflammatory mediators and host-response modifiers [6–8], host-derived enzymes and their inhibitors [9–11] and tissue breakdown products [12–14].
Among host-derived enzymes, positive association between alkaline phosphatase (ALP) and periodontal disease activity has previously been reported [15, 16]. This membrane-bound glycoprotein, which functions as a phospho-hydrolytic enzyme, is a calcium- and phosphate-binding protein . ALP is released from neutrophils and, thus, detected in GCF collected from inflamed periodontium as well as from osteoblasts during bone formation [18, 19]. With respect to tissue-breakdown products, several studies have investigated the levels of proteoglycans and their constituent glycosaminoglycans (GAGs) in periodontal tissues and GCF from patients with periodontal disease in comparison to those from healthy controls [20, 21]. Major GAGs present in periodontal tissues are dermatan sulfate, hyaluronan, chondroitin sulfate (CS) and keratan sulfate. A main source of GAGs in GCF is derived from extracellular matrix degradation of periodontal tissues during the progression of periodontal disease. Consequently, raised levels of GAGs detectable in GCF directly reflect, and are associated with the destruction of periodontal tissues, especially alveolar bone, at the diseased site [22–25]. Furthermore, elevated levels of CS in GCF are apparently associated with four clinical parameters of periodontal status, which serve as gold standards for periodontal inflammation and destruction . In addition to periodontal disease, CS levels can be precisely detected in physiologic tooth movement [26, 27] and in patients with pathologic inflammatory disorders, such as degenerative joint diseases [28, 29].
Although a number of studies have examined the relationship of each individual biochemical marker to different types and severity of periodontal diseases, there is still no study comparing the efficiency of different markers in evaluating disease severity. The aims of this study were, therefore, to investigate the levels of CS, as determined by our patented monoclonal antibody, raised against the WF6 catabolic epitope of CS , and of ALP in GCF obtained from patients with various disease statuses in comparison to healthy controls, and to compare the efficiency of these two biochemical markers in assessing the severity of periodontal diseases.
Forty-three patients, including 10 patients with gingivitis (5 males and 5 females) and 33 patients with chronic periodontitis (16 males and 17 females), were recruited from the Periodontology clinic, Faculty of Dentistry, Chiang Mai University along with ten healthy volunteers (5 males and 5 females). Written informed consent for participation in this study was obtained from all participants. They were diagnosed according to the classification of periodontal diseases by the American Academy of Periodontology (AAP) 1999 . The periodontal tissues of healthy controls did not exhibit any clinical signs of inflammation or destruction, whereas those of patients with gingivitis showed clinical signs of gingival inflammation and bleeding upon probing without periodontal pocket formation. The clinical features of patients with chronic periodontitis comprised gingival inflammation and bleeding and periodontal pocket formation from alveolar bone loss as evaluated by the radiography. Patients and volunteers with underlying systemic diseases were excluded from this study according to their medical history obtained from an interview with dental practitioners at the Oral Diagnostic Clinic, Faculty of Dentistry, Chiang Mai University. The participants recruited in this study were non-smoking and non-pregnant persons without periodontal treatment or a history of antibiotic or NSAID uses within three months prior to GCF sampling. The proposal was approved by the Human Experimentation Committee, Faculty of Dentistry, Chiang Mai University.
Five healthy sites from each healthy volunteer were selected as the healthy group (H), while five gingivitis sites from each patient with gingivitis were chosen as the gingivitis group (G). For patients with chronic periodontitis a total of 200 sites were randomly selected and divided into four groups according to a clinical attachment loss (CAL). Fifty sites with clinical signs of gingival inflammation and bleeding on probing without attachment loss were identified as gingivitis sites in the periodontitis group (PG), 50 sites with CAL 1–2 mm were identified as slight periodontitis group (PSL), 50 sites with CAL 3–4 mm were identified as moderate periodontitis group (PM), and 50 sites with CAL > 4 mm were identified as severe periodontitis group (PSE).
Clinical parameters, including probing depth (PD), gingival recession, CAL, plaque index (PI)  and gingival index (GI)  were recorded. The gingival recession and PD were measured using a PCP-UNC15 probe (Hu-Friedy, Chicago, IL, USA) from a reference point, the cementum-enamel junction, and both data were then combined and reported as CAL. All parameters were examined by one experienced periodontist (S.K.). The intra-examiner calibration was performed with 98% and 96% agreement for PD and CAL, respectively.
GCF sample collection
One week before GCF collection, all clinical parameters were recorded to avoid blood contamination during GCF sampling. The GCF collecting technique was performed as described previously . The selected site was isolated with cotton rolls and gently air dried with a triple syringe. Periopaper strips (ProFlow™, Amityville, NY, USA) and an analytical instrument (Periotron 8000™, Oralflow Inc., Plainview, NY, USA) were used to collect and measure the GCF volumes ranging from 0.04 to 1.76 μl. All of the GCF samples were individually stored at −80°C for further analyses. To recover biomolecules from Periopaper strips, a 100-μl quantity of phosphate-buffered saline was added and then agitated for 30 min at room temperature. The GCF was recovered from the Periopaper strips as previously described  with the recovery rate approximately 98%.
Competitive inhibition ELISA with WF6 monoclonal antibody (mAb)
To determine CS (WF6 epitope) levels, a quantitative ELISA method was performed using our WF6 mAb as described previously . Briefly, microtiter plates (Maxisorp®, Nunc, Roskilde, Denmark) were coated with 10 μg/ml shark PG-A1 fraction (100 μl/well)  in coating buffer (20 mM sodium carbonate buffer, pH 9.6) overnight at ambient temperature. The plates were then washed three times with 150 μl/well of Tris-incubation buffer (Tris-IB)  and dried. One hundred and fifty μl per well of 1% (w/v) bovine serum albumin (BSA) in Tris-IB was added to all plates and then incubated at 37°C for 60 min. Thereafter, 100 μl/well of the mixture, comprising 10 μl of GCF samples or of standard competitors (Shark PG-AlDl fraction; ranging from 39.06 to 10,000 ng/ml) in mAb against the WF6 epitope of CS (patent number WO 2005/118645 A1) at 1:100 dilution, were added in duplicate for 60 min at 37°C. Subsequently, the plates were washed, and the IgM-specific peroxidase-conjugated anti-mouse immunoglobulin (100 μl/well; 1:2,000) was added and incubated at 37°C for 60 min. The plates were washed and the peroxidase substrate (100 μl/well) was added at 37°C for 20 min to allow the color to develop. The reactions were stopped by addition of 50 μl/well of 4 M H2SO4. The absorbance ratio at 492:690 nm was measured using a Titertek Multiskan® MCC/340 multiplate reader (ICN/Flow Laboratories, Costa Mesa, CA, USA). The minimal detection level of ELISA for CS was 0.019 ng/ml. The CS concentration in each sample was normalized by its GCF volume, as measured by Periotron 8000™ .
Determination of ALP levels
The GCF samples were measured for ALP levels by using an Alkaline Phosphatase Detection kit (Sigma-Aldrich, St. Louis, MO, USA) according to the manufacturer’s instructions. Briefly, a 180 μl-quantity of fluorometric assay buffer was added to the mixture that contained 20 μl of GCF sample solution and 1 μl of 10 mM substrate solution (4-methylumbelliferyl phosphate disodium). Then, the mixtures were read at 360 nm for excitation wavelength and 440 nm for emission wavelength in triplicate using a Fluorometer (Synergy H4 Hybrid Multi-Mode Microplate Reader, Biotek®, Winooski, Vermont, USA). Known concentrations of an ALP control (Sigma-Aldrich) were prepared with the dilutions ranging from 0 to 1000 ng/ml. The concentrations of ALP in the GCF samples were measured and calculated from a standard curve of these known concentrations. The ALP concentration in each sample was normalized by its GCF volume, as measured by Periotron 8000™ .
The average age of participants was compared between groups by the paired t-test. The differences in clinical parameters between groups were analyzed by One-way ANOVA followed by Tukey’s post hoc test. The Kolmogorov-Smirnov test was used to determine the distribution of CS and ALP levels. The differences in the CS or the ALP levels among different severities of periodontal diseases were determined by the Wilcoxon signed-rank test, and the differences between the two groups of severities were determined by the Mann–Whitney U-test. The correlations between CS or ALP levels and clinical parameters were determined by Spearman’s correlation coefficient. The results were considered statistically significant when p-values were less than 0.05. Data were analyzed by using the Statistical Package for Social Sciences version 17.0 for Windows (SPSS Inc., Chicago, IL, USA).
Demographic data and periodontal parameters
Mean ages of healthy controls, patients with gingivitis, and patients with chronic periodontitis, were 27.80 ± 5.18, 26.5 ± 4.79 and 50.27 ± 9.67 years, respectively. No significant difference between the mean age of healthy controls and that of patients with gingivitis was found, whereas the mean age of patients with chronic periodontitis was significantly higher than that of the healthy controls and of the gingivitis group (p < 0.001). All four clinical parameters are illustrated in Table 1. With regard to clinical parameters of periodontal destruction, there were no significant differences in mean PD and CAL values between the healthy (H), gingivitis (G) and gingivitis sites in chronic periodontitis (PG) groups (Table 1). However, in patients with chronic periodontitis, mean PD and CAL values in the slightly (PSL), moderately (PM), and severely (PSE) destructive sites were progressively increased and to a significantly greater degree than those of non-destructive sites (p < 0.05) (Table 1). With respect to clinical parameters of periodontal inflammation, it was demonstrated that mean GI and PI scores of the PM and PSE groups were significantly higher than those of the other groups (p < 0.05) (Table 1).
Elevated CS and ALP levels in destructive sites of chronic periodontitis
Since the data distributions of CS and ALP levels were not normal, median values of these levels and non-parametric statistical methods were used to determine the differences among different degrees of disease severity. It was found that the median CS levels among the H (28.35 ng/ml), G (40.70 ng/ml), PG (34.80 ng/ml), and PSL groups (45.05 ng/ml) were not significantly different, while those of the PM (168.30 ng/ml) and PSE groups (330.15 ng/ml) were significantly higher than those in the other four groups (p < 0.001) (Figure 1). Furthermore, a significant difference in median CS levels between moderately and severely destructive sites (PM vs. PSE) was found (p < 0.001) (Figure 1). With respect to ALP levels, no significant differences between the H (19.10 ng/ml), G (21 ng/ml), PG (17.40 ng/ml) and PSL groups (19.10 ng/ml) were observed (Figure 2). In contrast to CS levels, the median ALP levels between moderately and severely destructive sites [PM (27.40 ng/ml) vs. the PSE group (37.05 ng/ml)] were not significantly different, although a significant difference was still observed between non-destructive to slightly destructive sites and moderately to severely destructive sites (p < 0.001) (Figure 2).
Strong correlations observed between CS levels and periodontal parameters
Correlations between CS or ALP levels and four periodontal parameters, including PD, CAL, GI and PI, were determined as shown in Figure 3. It was found that the CS concentrations were significantly correlated with PD and CAL values (r = 0.632 and 0.634, respectively, p < 0.001) (Figure 3A and B), whereas the ALP levels were weakly correlated with these values (r = 0.287 and 0.282, p < 0.001) (Figure 3E and F), indicating that the CS levels were associated with the degrees of periodontal tissue destruction more than were the ALP levels. Moreover, the CS concentrations were significantly correlated with GI and PI scores (r = 0.559 and 0.552, respectively, p < 0.001) (Figure 3C and D), whereas the ALP levels were slightly correlated with these values (r = 0.242 and 0.313, p < 0.001) (Figure 3G and H), reflecting that the correlation between the CS levels and the degrees of periodontal tissue inflammation is stronger than that between the ALP levels and the degrees of inflammation. In sum, these findings suggest that raised CS levels in GCF represent the degrees of periodontal tissue destruction and inflammation better than do elevated ALP levels.
In this study, it was demonstrated that both CS and ALP levels in GCF collected from patients with different periodontal disease statuses were raised in accordance with the severity of periodontal destruction. Low but detectable CS and ALP levels were observed in the H, G, PG and PSL groups, whereas these levels were significantly elevated in the PM and PSE groups when compared with the non-destructive to slightly destructive periodontitis groups. Interestingly, a significant difference in terms of CS levels between moderate and severe chronic periodontitis sites was demonstrated, whereas no significant difference in ALP levels was found. Furthermore, the levels of both biomolecules were significantly correlated with all of four periodontal parameters, including the degrees of periodontal destruction (PD and CAL) and of inflammation (GI and PI), but stronger correlations between all parameters and CS levels than between those and ALP levels were evident. The reason we chose to study the GCF levels of CS and ALP was because it was previously demonstrated that elevated levels of these two biomolecules were closely associated with alveolar bone destruction in chronic periodontitis [14, 35], whereas raised levels of other biomolecules, such as host-derived pro-inflammatory mediators and proteolytic enzymes, can reflect enhanced inflammation and destruction of both soft and hard periodontal tissues. Therefore, we believe that among a number of biomolecules found within GCF, CS and ALP are good candidates for this comparative study to assess the different severities of alveolar bone destruction in chronic periodontitis.
As anticipated, the average age of patients with chronic periodontitis was more than those with gingivitis and healthy controls due to the chronic nature of periodontitis, which is caused by dental plaque accumulation and persistent inflammation of nearby periodontal tissues. Nevertheless, the CS and ALP levels from the gingivitis sites of patients with chronic periodontitis (PG) were not significantly different from those of both patients with gingivitis (G) and of healthy participants (H), although the ages of patients and healthy volunteers in this study were not matched. In contrast to the age difference between the chronic periodontitis and the remaining groups, the gender distribution was not different among groups to avoid bias in the study design. Furthermore, no significant differences in clinical parameters between the H, G and PG groups were found, whereas such parameters in PSL, PM and PSE groups were enhanced according to the severity of periodontitis.
In other previous reports, the studied cohorts were mostly defined as healthy, gingivitis and chronic periodontitis [13, 35]. However, in our study, the chronic periodontitis group was further divided into subgroups, including PG, PSL, PM, and PSE, according to the disease severity. We believe that detailed classification of chronic periodontitis according to the severity of alveolar bone destruction will better reflect the potential of biochemical markers to distinguish different disease statuses that can provide useful information and help clinicians in proper treatment planning and periodontal maintenance, while the conventional clinical parameters cannot [36, 37].
In some previous studies, the association between ALP and periodontal disease was reported, especially in active diseased sites [16, 35]. Significantly higher concentrations of ALP were observed in periodontitis than in healthy and gingivitis sites, and positive correlations of ALP levels with clinical parameters, including PD and GI, were reported [16, 38]. These findings were similar to ours, and weak correlations were also demonstrated both in those studies and ours. With respect to CS levels, significantly higher levels were shown in destructive sites than in non-destructive or in slightly destructive sites, consistent with the findings from our previous study . Interestingly, even though the ALP levels were higher in the destructive sites, no significant difference in ALP levels was found between moderate and severe destruction. On the other hand, a significant difference in CS levels between moderate and severe destruction was observed, suggesting that the CS levels can be better used than the ALP levels, to differentiate the clinical severity of periodontitis, especially between moderate and severe periodontal destruction, although the levels of both biomolecules were elevated in the GCF of patients with chronic periodontitis.
It was demonstrated in this study that either CS or ALP levels were positively correlated with all four clinical parameters, which represent periodontal destruction and inflammation. The positive correlations of elevated CS and ALP levels with increased clinical severity are in line with the findings from previous studies [14, 17, 35]. However, in this study, all four correlations between the clinical parameters and CS levels were stronger than those between clinical parameters and ALP levels, corresponding with the ability of CS levels, but not ALP levels, to differentiate between moderate and severe periodontal destruction as mentioned above. This may be because CS is derived only from destruction of host extracellular matrix , whereas ALP can be derived from both bacterial cells  and host cells [41–43]. Moreover, it is recognized that raised CS levels are principally due to alveolar bone resorption, whereas elevated ALP levels are found to be implicated in the process of bone formation  in addition to bone resorption in destructive sites [35, 44]. Lastly, CS is a repeating disaccharide unit of GAGs and should not be cleaved by GCF proteinases, derived from both periodontal pathogens and host cells , whereas ALP enzyme can be degraded by these proteinases during GCF storage. There is still a limitation of this study due to its cross-sectional design; thus, a further longitudinal study is required to monitor any alterations in the GCF levels of these two biomolecules during periodontal disease progression in each individual tooth.
In summary, CS is a better biochemical marker to differentiate moderate and severe alveolar bone destruction and shows stronger correlations with all four clinical parameters than ALP. It is, therefore, suggested by all of the findings from this study that CS is a better biochemical marker for evaluating periodontal disease severity than is ALP.
Armitage GC: Diagnosis of periodontal diseases. J Periodontol. 2003, 74: 1237-1247.
Lamster IB, Ahlo JK: Analysis of gingival crevicular fluid as applied to the diagnosis of oral and systemic diseases. Ann N Y Acad Sci. 2007, 1098: 216-229. 10.1196/annals.1384.027.
Luo L, Xie P, Gong P, Tang XH, Ding Y, Deng LX: Expression of HMGB1 and HMGN2 in gingival tissues, GCF and PICF of periodontitis patients and peri-implantitis. Arch Oral Biol. 2011, 56: 1106-1111. 10.1016/j.archoralbio.2011.03.020.
Bakri I, Douglas CW, Rawlinson A: The effects of stress on periodontal treatment: a longitudinal investigation using clinical and biological markers. J Clin Periodontol. 2013, 40: 955-961. 10.1111/jcpe.12142.
Gupta G: Gingival crevicular fluid as a periodontal diagnostic indicator- I: Host derived enzymes and tissue breakdown products. J Med Life. 2012, 5 (4): 390-397.
Rawlinson A, Grummitt JM, Walsh TF, Ian Douglas CW: Interleukin 1 and receptor antagonist levels in gingival crevicular fluid in heavy smokers versus non-smokers. J Clin Periodontol. 2003, 30: 42-48. 10.1034/j.1600-051X.2003.300107.x.
Javed F, Al-Hezaimi K, Salameh Z, Almas K, Romanos GE: Proinflammatory cytokines in the crevicular fluid of patients with peri-implantitis. Cytokine. 2011, 53: 8-12. 10.1016/j.cyto.2010.08.013.
Becerik S, Öztürk VÖ, Atmaca H, Atilla G, Emingil G: Gingival crevicular fluid and plasma acute-phase cytokine levels in different periodontal diseases. J Periodontol. 2012, 83: 1304-1313. 10.1902/jop.2012.110616.
Reinhardt RA, Stoner JA, Golub LM, Lee HM, Nummikoski PV, Sorsa T, Payne JB: Association of gingival crevicular fluid biomarkers during periodontal maintenance with subsequent progressive periodontitis. J Periodontol. 2010, 81: 251-259. 10.1902/jop.2009.090374.
Lee JH, Choi YJ, Heo SH, Lee JM, Cho JY: Tumor necrosis factor-α converting enzyme (TACE) increases RANKL expression in osteoblasts and serves as a potential biomarker of periodontitis. BMB Rep. 2011, 44: 473-477. 10.5483/BMBRep.2011.44.7.473.
Tsuchida S, Satoh M, Kawashima Y, Sogawa K, Kado S, Sawai S, Nishimura M, Ogita M, Takeuchi Y, Kobyashi H, Aoki A, Kodera Y, Matsushita K, Izumi Y, Nomura F: Application of quantitative proteomic analysis using tandem mass tags for discovery and identification of novel biomarkers in periodontal disease. Proteomics. 2013, 13: 2339-2350. 10.1002/pmic.201200510.
Huri CB, Yamalik N, Kilinç K, Kilinç A, Etikan I, Eratalay K: Analysis of the relationship between the severity of periodontal destruction and proteoglycan metabolism of gingiva and gingival crevicular flu. J Clin Periodontol. 2003, 30: 961-968. 10.1034/j.1600-051X.2003.00408.x.
Bostanci N, Ilgenli T, Emingil G, Afacan B, Han B, Töz H, Atilla G, Hughes FJ, Belibasakis GN: Gingival crevicular fluid levels of RANKL and OPG in periodontal diseases: implications of their relative ratio. J Clin Periodontol. 2007, 34: 370-376. 10.1111/j.1600-051X.2007.01061.x.
Khongkhunthian S, Srimueang N, Krisanaprakornkit S, Pattanaporn K, Ong-Chai S, Kongtawelert P: Raised chondroitin sulphate WF6 epitope levels in gingival crevicular fluid in chronic periodontitis. J Clin Periodontol. 2008, 35: 871-876. 10.1111/j.1600-051X.2008.01312.x.
Ishikawa I, Cimasoni G: Alkaline phosphatase in human gingival fluid and its relation to periodontitis. Arch Oral Biol. 1970, 15: 1401-1404. 10.1016/0003-9969(70)90032-4.
Nakashima K, Giannopoulou C, Andersen E, Roehrich N, Brochut P, Dubrez B, Cimasoni G: A longitudinal study of various crevicular fluid components as markers of periodontal disease activity. J Clin Periodontol. 1996, 23: 832-838. 10.1111/j.1600-051X.1996.tb00620.x.
Bezerra Júnior AA, Pallos D, Cortelli JR, Saraceni CHC, Queiroz CS: Evaluation of organic and inorganic compounds in the saliva of patients with chronic periodontal disease. Rev Odonto Ciênc. 2010, 25: 234-238. 10.1590/S1980-65232010000300003.
Chapple IL, Glenwright HD, Matthews JB, Thorpe GH, Lumley PJ: Site-specific alkaline phosphatase levels in gingival crevicular fluid in health and gingivitis: cross-sectional studies. J Clin Periodontol. 1994, 21: 409-414. 10.1111/j.1600-051X.1994.tb00738.x.
Perinetti G, Paolantonio M, Femminella B, Serra E, Spoto G: Gingival crevicular fluid alkaline phosphatase activity reflects periodontal healing / recurrent inflammation phases in chronic periodontitis patients. J Periodontol. 2008, 79: 1200-1207. 10.1902/jop.2008.070519.
Smith AJ, Addy M, Embery G: Gingival crevicular fluid glycosaminoglycan levels in patients with chronic adult periodontitis. J Clin Periodontol. 1995, 22: 355-361. 10.1111/j.1600-051X.1995.tb00161.x.
Vardar S, Baylas H, Zihnioğlu F, Emingil G, Buduneli N, Atilla G: Total proteoglycan and chondroitin-4-sulfate levels in gingiva of patients with various types of periodontitis. J Periodontol. 2004, 75: 393-398. 10.1902/jop.2004.75.3.393.
Oksala O, Haapasalmi K, Häkkinen L, Uitto VJ, Larjava H: Expression of heparan sulphate and small dermatan/chondroitin sulphate proteoglycans in chronically inflamed human periodontium. J Dent Res. 1997, 76: 1250-1259. 10.1177/00220345970760060401.
Utoh E, Okazaki J, Gonda Y: Analysis of hyaluronic acid in human gingival crevicular fluid using high-performance liquid chromatography. J Osaka Dent Univ. 1998, 32: 1-7.
Waddington RJ, Langley MS, Guida L, Iuorio G, Labella R, Embery G, Caruso F: Relationship of sulphated glycosaminoglycans in human gingival crevicular fluid with active periodontal disease. J Periodontal Res. 1996, 31: 168-170. 10.1111/j.1600-0765.1996.tb00480.x.
Waddington RJ, Embery G, Smith AJ: Immunochemical detection of the proteoglycans decorin and biglycan in human gingival crevicular fluid from sites of advanced periodontitis. Arch Oral Biol. 1998, 43: 287-295. 10.1016/S0003-9969(97)00119-2.
Intachai I, Krisanaprakornkit S, Kongtawelert P, Ong-chai S, Buranastidporn B, Suzuki EY, Jotikasthira D: Chondroitin sulphate (WF6 epitope) levels in peri-miniscrew implant crevicular fluid during orthodontic loading. Eur J Orthod. 2010, 32: 60-65. 10.1093/ejo/cjp056.
Insee K, Pothacharoen P, Kongtawelert P, Ongchai S, Jotikasthira D, Krisanaprakornkit S: Comparisons of the chondroitin sulphate levels in orthodontically moved canines and the clinical outcomes between two different force magnitudes. Eur J Orthod. 2014, 36: 39-46. 10.1093/ejo/cjs109.
Nganvongpanit K, Itthiarbha A, Ong-Chai S, Kongtawelert P: Evaluation of serum chondroitin sulfate and hyaluronan: biomarkers for osteoarthritis in canine hip dysplasia. J Vet Sci. 2008, 9: 317-325. 10.4142/jvs.2008.9.3.317.
Pruksakorn D, Rojanasthien S, Pothacharoen P, Luevitoonvechkij S, Wongtreratanachai P, Ong-Chai S, Kongtawelert P: Chondroitin sulfate epitope (WF6) and hyaluronic acid as serum markers of cartilage degeneration in patients following anterior cruciate ligament injury. J Sci Med Sport. 2009, 12: 445-448. 10.1016/j.jsams.2008.02.003.
Pothacharoen P, Kalayanamitra K, Deepa SS, Fukui S, Hattori T, Fukushima N, Hardingham T, Kongtawelert P, Sugahara K: Two related but distinct chondroitin sulfate mimetope octasaccharide sequences recognized by monoclonal antibody WF6. J Biol Chem. 2007, 282: 35232-35246. 10.1074/jbc.M702255200.
Armitage GC: Periodontal diagnoses and classification of periodontal diseases. Periodontol 2000. 2004, 34: 9-21. 10.1046/j.0906-6713.2002.003421.x.
Silness J, Löe H: Periodontal disease in pregnancy II: correlation between oral hygiene and periodontal conditions. Acta Odontol Scand. 1964, 22: 121-135. 10.3109/00016356408993968.
Löe H, Silness J: Periodontal disease in pregnancy. I. Prevalence and severity. Acta Odontol Scand. 1963, 21: 533-551. 10.3109/00016356309011240.
Makeudom A, Kulpawaropas S, Montreekachon P, Khongkhunthian S, Sastraruji T, Pothacharoen P, Kongtawelert P, Krisanaprakornkit S: Positive correlations between hCAP18/LL-37 and chondroitin sulphate levels in chronic periodontitis. J Clin Periodontol. 2014, 41: 252-261. 10.1111/jcpe.12216.
Sanikop S, Patil S, Agrawal P: Gingival crevicular fluid alkaline phosphatase as a potential diagnostic marker of periodontal disease. J Indian Soc Periodontol. 2012, 16: 513-518. 10.4103/0972-124X.106889.
Taba M, Kinney J, Kim AS, Giannobile WV: Diagnostic Biomarkers for Oral and Periodontal Diseases. Dent Clin N Am. 2005, 49: 551-571. 10.1016/j.cden.2005.03.009.
Todorovic T, Dozic I, Vicente-Barrero M, Ljuskovic B, Pejovic J, Marjanovic M, Knezevic M: Salivary enzymes and periodontal disease. Med Oral Patol Oral Cir Bucal. 2006, 11: E115-E119.
Nakashima K, Roehrich N, Cimasoni G: Osteocalcin, prostaglandin E2 and alkaline phosphatase in gingival crevicular fluid: their relations to periodontal status. J Clin Periodontol. 1994, 21: 327-333. 10.1111/j.1600-051X.1994.tb00721.x.
Cho M-I, Garant PR: Development and general structure of the periodontium. Periodontol 2000. 2000, 24: 9-27. 10.1034/j.1600-0757.2000.2240102.x.
Loos BG, Tjoa S: Host-derived diagnostic markers for periodontitis: do they exist in gingival crevice fluid?. Periodontol. 2005, 39: 53-72. 10.1111/j.1600-0757.2005.00129.x.
Whyte MP, Landt M, Ryan LM, Mulivor RA, Henthorn PS, Fedde KN, Mahuren JD, Coburn SP: Alkaline phosphatase: placental and tissue-nonspecific isoenzyms hydrolyze phosphoethanolamine, inorganic pyrophosphate, and pyridoxal 5’-phosphate. Substrate accumulation in carriers of hypophosphatasia corrects during pregnancy. J Clin Invest. 1995, 95: 1440-1445. 10.1172/JCI117814.
Yoshinari K, Matsumoto K, Misaki H: Differential patterns of expression of glycosylphosphatidylinositol-anchored carcinoembryonic antigen and alkaline phosphatase in various cancer cell lines. Cytotechnology. 1999, 31: 255-263. 10.1023/A:1008061424281.
Ferianec V, Linhartová L: Extreme elevation of placental alkaline phsphatase as a marker of preterm delivery, placental insufficiency and low birth weight. Neuro Endocrinol Lett. 2011, 32: 154-157.
Daltaban O, Saygun I, Bal B, Baloş K, Serdar M: Gingival crevicular fluid alkaline phosphatase levels in postmenopausal women: Effects of phase I periodontal treatment. J Periodontol. 2006, 77: 67-72. 10.1902/jop.2006.77.1.67.
Sorsa T, Tjäderhane L, Konttinen YT, Lauhio A, Salo T, Lee HM, Golub LM, Brown DL, Mäntylä P: Matrix metalloproteinases: contribution to pathogenesis, diagnosis and treatment of periodontal inflammation. Ann Med. 2006, 38: 306-321. 10.1080/07853890600800103.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6831/14/107/prepub
We thank the Intramural Endowment Fund, Faculty of Dentistry, Chiang Mai University; the Discovery Based Development Grant (P-10-11290), National Science and Technology Development Agency, Ministry of Science and Technology; and the Thailand Research Fund to S.K. (BRG5680001) for financially supporting this study. We also thank Dr. M. Kevin O Carroll, Professor Emeritus of the University of Mississippi School of Dentistry, USA, and Faculty Consultant at Chiang Mai University Faculty of Dentistry, Thailand, for his critical reading of this manuscript.
All authors declare that they have no competing interests.
SK: Recruitment of patients and volunteers; site selection; periodontal examination; GCF sample collections. PK: Measurement of chondroitin sulfate levels. SO: Measurement of chondroitin sulfate levels. PP: Measurement of alkaline phosphatase levels. TS: Statistical analyses. DJ: Manuscript preparation. SK: Manuscript preparation and corresponding author. We would like to declare that all authors read and approved the final version of this manuscript.
About this article
Cite this article
Khongkhunthian, S., Kongtawelert, P., Ongchai, S. et al. Comparisons between two biochemical markers in evaluating periodontal disease severity: a cross-sectional study. BMC Oral Health 14, 107 (2014). https://doi.org/10.1186/1472-6831-14-107
- Alkaline phosphatase
- Chondroitin sulfate
- Chronic periodontitis
- Gingival crevicular fluid